Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service, Merger/Acquisition

KabaFusion Acquires Lincare's Infusion Pharmacies, Expanding Patient-Focused Home Infusion Services Nationwide


KabaFusion, a leading provider of specialty acute and chronic home infusion therapies, today announced it has acquired the home infusion assets of Lincare, a subsidiary of Linde plc. The strategic combination strengthens KabaFusion's position as the premier clinician-led home infusion company in the United States, significantly enhancing the company's ability to deliver superior patient care across a broad range of home infusion therapies nationwide.

KabaFusion, led by founder Dr. Sohail Masood, has been a pioneering leader in patient-focused home infusion services with deep clinical expertise in intravenous immunoglobulin (IVIG) therapies. The addition of Lincare's infusion operations expands KabaFusion's footprint to 28 home infusion specialty pharmacies, adding key strategic markets in Alabama, Arkansas, Florida, Indiana, Kentucky, Michigan, New Jersey, New York, North Carolina, Virginia and Wyoming. Together with KabaFusion's existing pharmacies in California, Florida, Illinois, Massachusetts, New Jersey, Pennsylvania and Texas, the company is licensed to serve patients in 44 states with a comprehensive offering of acute, chronic and enteral therapies.

"We are excited to expand our national network with the infusion pharmacies from Lincare, who shares our values and our deep commitment to patient care" said Dr. Sohail Masood, founder and Chief Executive Officer of KabaFusion. "We look forward to combining the best of both our teams, as together we will be even better positioned to continue delivering high-quality home infusion services to achieve the best possible outcome for each of our patients."

The transaction marks KabaFusion's first acquisition since partnering with Pritzker Private Capital in January 2019. Ceron Rhee of Pritzker Private Capital commented, "We are pleased to welcome Lincare's infusion team to the KabaFusion and Pritzker Private Capital families. The combination of KabaFusion's patient-focused leadership in IVIG with Lincare's long-standing presence in complementary markets uniquely positions the company for continued exceptional growth under Dr. Masood's leadership."

KabaFusion's clinician-led management team will continue to lead the combined company in working with patients, healthcare providers, hospitals and payors across the United States to deliver the highest quality home infusion services with unmatched clinical excellence. Terms of the transaction were not disclosed.

About KabaFusion

KabaFusion was founded by Dr. Sohail Masood, Pharm D., in 2010 and operates 28 home infusion specialty pharmacies strategically located in California, Alabama, Arkansas, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan, New Jersey, New York, North Carolina, Pennsylvania, Texas, Virginia and Wyoming. KabaFusion is guided by a commitment to positive clinical outcomes and excellence in specialty acute and chronic therapies including intravenous immunoglobulin (IVIG). The company is dedicated to working proactively with patients, healthcare practitioners and payors to provide comprehensive support before, during and after treatment. For more information, visit www.KabaFusion.com.

About Pritzker Private Capital

Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products, services and healthcare sectors. The firm's differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur and family owned companies. For more information, visit www.ppcpartners.com.


These press releases may also interest you

at 21:05
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...

at 21:00
Research from Omdia's newly released Large Area Display Market Tracker 4Q23 has found shipments of large-area displays (all displays above 9inches), including both LCD and OLED, are forecasted to increase by 7.4% year-over-year (YoY) in units and...

at 20:56
Freed-Hardeman University will offer a new computer engineering program in the fall of 2024, providing students with the opportunity to enter a first cohort for a Bachelor of Science in engineering...

at 20:55
Quorum Information Technologies Inc. ("Quorum"), a North American SaaS Software and Services company providing essential enterprise solutions that automotive dealerships and Original Equipment Manufacturers ("OEMs") rely on for their operations,...

at 20:16
Evolution Equity Partners announced the final closing of Evolution Technology Fund III, LP on April 16th, 2024, and total capital commitments of $ 1.1 Billion to back visionary entrepreneurs building next generation...



News published on and distributed by: